fentanyl + dezocine + butorphanol

fentanyl + dezocine + butorphanol is a triple-combination opioid analgesic regimen primarily utilized in the management of moderate-to-severe postoperative pain, often administered via intravenous patient-controlled analgesia (IV-PCA). This combination therapy integrates fentanyl, a potent synthetic mu-opioid receptor agonist, with dezocine and butorphanol, both of which act as kappa-opioid receptor agonists and mu-opioid receptor partial agonists/antagonists. The rationale behind this combination is to achieve superior analgesic synergy while minimizing the dose-dependent side effects associated with pure mu-agonists, such as respiratory depression, pruritus, and gastrointestinal distress. Clinical research, notably from institutions like the Shanghai First People's Hospital, Baoshan Branch, has evaluated this specific mixture for its efficacy in providing stable hemodynamics and high patient satisfaction scores following surgical procedures.

Other names

fentanyl-dezocine-butorphanol combination